PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
24.98%
Revenue growth above 1.5x META's 12.29%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
21.12%
Gross profit growth above 1.5x META's 12.33%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
23.28%
EBIT growth above 1.5x META's 10.27%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
23.28%
Operating income growth 1.25-1.5x META's 16.44%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
23.72%
Net income growth above 1.5x META's 10.17%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
-11.54%
Negative EPS growth while META is at 10.47%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-11.54%
Negative diluted EPS growth while META is at 11.04%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
38.33%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
40.71%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-43.36%
Negative OCF growth while META is at 6.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.24%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
152.68%
10Y revenue/share CAGR under 50% of META's 1223.16%. Michael Burry would suspect a lasting competitive disadvantage.
152.68%
5Y revenue/share CAGR at 75-90% of META's 190.49%. Bill Ackman would encourage strategies to match competitor’s pace.
152.68%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.38%
Below 50% of META's 2770.56%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
21.38%
Below 50% of META's 304.58%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
21.38%
Below 50% of META's 194.47%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.34%
Our R&D shrinks while META invests at 6.52%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-100.00%
We cut SG&A while META invests at 12.01%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.